^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TTX-080
i
Other names: TTX-080, TTX 080, TTX080
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Tizona Therap
Drug class:
HLA G inhibitor
Related drugs:
2ms
TTX-080-001: TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
P1, N=240, Recruiting, Tizona Therapeutics, Inc | Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2024 --> Jun 2027
Enrollment open • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • TTX-080
2ms
TTX-080-001: TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
P1, N=240, Active, not recruiting, Tizona Therapeutics, Inc | Trial completion date: Jun 2024 --> Jun 2027 | Trial primary completion date: Dec 2023 --> Jun 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • TTX-080
12ms
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
P1, N=240, Active, not recruiting, Tizona Therapeutics, Inc | Phase classification: P1a/1b --> P1
Phase classification • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • TTX-080
over1year
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
P1a/1b, N=240, Active, not recruiting, Tizona Therapeutics, Inc | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2023 --> Dec 2023
Enrollment closed • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • TTX-080
Share via
